Title
CPT1A/2-Mediated FAO Enhancement-A Metabolic Target in Radioresistant Breast Cancer.

Permalink
https://escholarship.org/uc/item/5030409t

Journal
Frontiers in oncology, 9

ISSN
2234-943X

Authors
Han, Shujun
Wei, Ryan
Zhang, Xiaodi
et al.

Publication Date
2019

DOI
10.3389/fonc.2019.01201

Peer reviewed
CPT1A/2-Mediated FAO Enhancement—A Metabolic Target in Radioresistant Breast Cancer

Shujun Han 1,2†, Ryan Wei 1,3†, Xiaodi Zhang 1‡, Nian Jiang 1‡, Ming Fan 1, Jie Hunter Huang 1, Bowen Xie 1‡, Lu Zhang 1‡, Weili Miao 4, Ashley Chen-Ping Butler 1, Matthew A. Coleman 1,5, Andrew T. Vaughan 1,6, Yinsheng Wang 4, Hong-Wu Chen 5,6, Jiankang Liu 1,5 and Jian Jian Li 1,5‡

Tumor cells, including cancer stem cells (CSCs) resistant to radio- and chemotherapy, must enhance metabolism to meet the extra energy demands to repair and survive such genotoxic conditions. However, such stress-induced adaptive metabolic alterations, especially in cancer cells that survive radiotherapy, remain unresolved. In this study, we found that CPT1 (Carnitine palmitoyl transferase I) and CPT2 (Carnitine palmitoyl transferase II), a pair of rate-limiting enzymes for mitochondrial fatty acid transportation, play a critical role in increasing fatty acid oxidation (FAO) required for the cellular fuel demands in radioresistant breast cancer cells (RBCs) and radiation-derived breast cancer stem cells (RD-BCSCs). Enhanced CPT1A/CPT2 expression was detected in the recurrent human breast cancers and associated with a worse prognosis in breast cancer patients. Blocking FAO via a FAO inhibitor or by CRISPR-mediated CPT1A/CPT2 gene deficiency inhibited radiation-induced ERK activation and aggressive growth and radioresistance of RBCs and RD-BCSCs. These results revealed that switching to FAO contributes to radiation-induced mitochondrial energy metabolism, and CPT1A/CPT2 is a potential metabolic target in cancer radiotherapy.

Keywords: breast cancer stem cells, CPT1A/CPT2, FAO, metabolism, radioresistance, breast cancer

INTRODUCTION

Radiation therapy (RT) is the major modality in treatment of solid cancer, including breast cancer (BC), with reported clinical benefits (1, 2). A meta-analysis of 10,801 women with or without RT after breast-conserving surgery in randomized trials demonstrated that RT reduced the 10-year risk of any first recurrence (locoregional or distant tumors) from 35.0 to 19.3% and reduced the 15-year risk of BC mortality rate from 25.2 to 21.4% (1). Cancer stem cells (CSCs; also termed as tumor-initiating cells, TICs) are suggested to be the carcinogenic cell source and responsible for tumor aggressive phenotype and failure of anti-tumor therapy (3, 4). To further improve the BC long-term efficacy by RT, the mechanisms linked with the adaptive radioresistance and recurrent risk in CSCs are to be investigated (5–8).
Elucidation of the metabolic dynamics of resistant breast cancer cells (RBCs) will help to identify metabolic targets to synergize the efficacy of RT. The theory of aerobic glycolysis in malignant cells (Warburg Effect) (9–11) is being updated, with emerging new evidence indicating an adaptive energy reprogramming in tumor cells with mitochondrial reactivation and oxidative phosphorylation (12, 13). We have reported that mitochondrial MnSOD activity is required for radioresistance in BC cells (14, 15) and radiation can enhance mitochondrial OXPHOS in tumor cells (16). Enhanced mitochondrial bioenergetics are found to be the major cellular fuel supplement for cell cycle progression (17–19), tumor aggressive phenotype and metastasis (20). Accumulating new evidence indicates that reprogramming in mitochondrial metabolism is actively involved in tumor proliferation and metastasis (12, 21–23). Mitochondrial energy output is also required for nuclear DNA repair after IR (24), and mitochondrial FAO is linked with BC metastasis (25, 26). With such a flexible adaptive energy metabolism detected in the malignant cells (13, 27), it is reasonable to look into the deep mechanistic insights of reprogramming mitochondrial bioenergetics in aggressive tumors, especially the RBCs.

Under genotoxic stress conditions, such as chemotherapy or radiotherapy, tumor cells must acquire additional cellular fuel resource to meet the increased demands of energy consumption for damage repair and survive (24). In addition to glucose, fatty acids with high ATP yield are a relevant energy-rich source in cancer cells under such genotoxic crisis. The FAO-mediated mitochondrial bioenergetics has been assumed to play a critical role in cell proliferation, cancer stemness and chemoresistance (28–30). Inhibition of mitochondrial FAO by etomoxir impairs NADPH production and increases reactive oxygen species (ROS), resulting in ATP depletion and cell death in human glioblastoma cells (31). In mitochondrial FAO pathways, targeting CPT1A generates clinic benefits in RT for nasopharyngeal carcinoma patients (32). However, the precise network of FAO enhancement in reprogramming mitochondrial energy metabolism, especially in resistant breast cancer cells, remains to be elucidated.

To mimic clinical radioresistance, in this study, RBCs were generated from wild type breast cancer cells via continuous ionizing radiation (IR), and the radioresistant BCSCs cells were sorted from the RBCs (8), termed as radiation-derived BCSCs (RD-BCSCs). Using proteomics of RD-BCSCs and CRISPR-mediated FAO gene editing, here we revealed a novel mitochondrial lipid metabolic reprogramming in RBCs and RD-BCSCs. The mitochondrial fatty acid oxidation (FAO) was enhanced in both RBCs and RD-BCSCs and linked with recurrent BC and a worse prognosis in BC patients. Blocking FAO by CRISPR-mediated CPT1A/CPT2 KO inhibited aggressive phenotype of the radioresistant BC with down-regulation of the ERK pathway, indicating a potential metabolic target in breast cancer radiotherapy.

MATERIALS AND METHODS

RBCs, RD-BCSCs, and Other Reagents

MCF7 and MDA-MB-231 human breast cancer cells were purchased from ATCC (Manassas, VA, USA). MCF7/C6 radioresistant clone is a single clone surviving from MCF7/WT cells after fractionated ionizing radiation treatment (2 Gy × 15) (33, 34). MDA-MB-231/C4 are radioresistant breast cancer cells surviving from MDA-MB-231/WT cells after fractionated radiation (2 Gy × 30) (35). MCF7, MCF7/C6, MDA-MB-231, and MDA-MB-231/C4 cells were cultured in DMEM medium with 10% fetal bovine serum (FBS, Life Technologies, NY, USA) and 1% penicillin/streptomycin (Life Technologies). RD-BCSCs were sorted as previously described (8, 36). Cell pellets of MCF7/C6 were rinsed with cold PBS with 2% FBS and then suspended with PBS containing 0.5% FBS and 0.5 mg/mL PI (Sigma, St. Louis, MO, USA). Then, the cell suspension was sorted using Cytopeia influx Cell Sorter (BD Biosciences, San Jose, CA, USA). The antibody against HER2/neu was conjugated to allophycocyanin (APC, BD Biosciences, San Jose, CA), anti-human CD44 was conjugated to FITC, and human CD24 was conjugated to phycoerythrin (PE; Invitrogen, Carlsbad, CA). Cell viability was assessed by 7-AF staining during cell sorting and then determined by trypan blue exclusion after sorting (Figure S1A). The isolated RD-BCSCs (CD44+/CD24−/low/HER2+) were maintained in CSC medium containing free serum and supplemented with B27 (Life Technology, Carlsbad, CA, USA), 20 ng/ml EGF (Biovision, Mountain View, CA, USA), 20 ng/ml basic-FGF, and 4 μg/ml heparin (VWR, Philadelphia, PA, USA). Cells were cultured in ultralow-attachment Petri dishes with 5% CO2 at 37°C. All cell lines were tested mycoplasma free before experiments. Etomoxir was purchased from Sigma-Aldrich. Oil Red O was obtained from Millipore Sigma (St. Louis, MO, USA).

Western Blot

Western blot was performed as previously described (37). Briefly, the cell lysates were separated on SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% milk for 1 h, and then incubated with primary antibodies with shaking at 4°C overnight. In the next day, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The protein blots were developed using an enhanced chemiluminescence western blot detection system (BioRad, Hercules, CA, USA). Antibodies against HER2/Neu (C-18, #SC284), CPT2 (G-5, #SC-377294), HADHA (E-8, #SC374497), HADHB (E-1, #SC-271495), ERK1/2 (C-9, #SC514302), and c-Fos (E-8, SC#166940) were all diluted at 1:500 and purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-CPT1A (clone D3B3, #12252), Phospho-p44/42 MAPK (Thr202/Tyr204, clone 197G2, #4377), Phospho-GSK3 β (Ser9, #9336), GSK3 β (clone 27C10, #9315), Phospho-STAT3 (Ser727, clone D8C22Z, #91499), and Phospho-JNK (Thr183/Tyr185, #9251) were from Cell Signaling Technology (Beverly, MA, USA). Antibody against ACAD9 (#3170340688) was purchased from Novus Biologicals (Littleton, CO, USA). Anti-β-actin at 1:2000 (#A2066) was from Sigma-Aldrich.

Fatty Acid Oxidation (FAO) Assay

FAO measurement was following the manufacturer’s instruction of Fatty Acid Oxidation Assay Kits from Abcam (ab217602). Briefly, 3 × 10^4 cells were seeded per well in 96-well plates and cultured overnight. Then the cells were rinsed twice with 100
µL prewarmed FA-Free medium followed by adding 90 µL pre-
warmed FA Measurement Medium. The wells without cells were
used as signal control. A total of 85 µL of FA-Free Measurement
medium was added to the wells, and 5 µL of BSA control
were included as the FA-free control. All wells except the blank
control had 10 µL Extracellular O2 Consumption Reagent added.
The FAO activator FCCP (0.625 µM) and inhibitor Etomoxir
(40 µM) were added as the positive and negative controls. Then
the wells were sealed with 100 µL pre-warmed mineral oil,
and the FAO was measured using the condition as Extracellular
Oxygen Consumption. The results were normalized by the
protein concentration with the cells in each sample under the
BCA assay.

Lipid Accumulation Assay
Breast cancer cells were plated and cultured in 96-well plates. In
the next day, cells were treated with 250 µM free fatty acid (oleic
acid: palmitate acid = 2:1) for 48 h. After being washed with PBS
twice, cells were fixed with 4% paraformaldehyde under room
temperature (RT) for 30 min. Cells were washed with sterilized
water once and added into 50 µL Oil Red working solution;
then they were incubated for 15 min at RT. Then 50 µL 60%
isopropanol was added to the cells for 20 s at RT. Finally, the
cells were washed with water twice, and the images were obtained
using a Nikon microscope (Eclipse, E1000M, Japan). The red oil
dye was eluted with 50 µL DMSO and incubated for 10 min with
gentle shaking. The lipid accumulation results were determined
by the fluorescence microplate spectrophotometer (Molecular
Devices) at 510 nm.

Oxygen Consumption
Extracellular Oxygen Consumption detection was performed
following the instruction of kit from Abcam (ab197243,) with
3 × 10⁴ cells seeded per well in 96-well plates and cultured at
37°C overnight. The cell medium was replaced with 150 µL fresh
culture media followed by adding 10 µL of extracellular oxygen
consumption reagent. The wells without oxygen consumption
reagent were used as blank control. Wells with Etomoxir
(40 µM) added were included as the negative control. Wells
had 100 µL of pre-warmed mineral oil added to avoid the air
bubbles. The plates were read immediately in a fluorescence
microplate spectrophotometer (Molecular Devices) at 37°C. The
signals were collected at 1.5 min intervals for 90-120 min at
Ex/Em = 380/650 nm. The results were normalized by protein
centration of the cells in each sample under the BCA assay.

MTT Assay
Breast cancer cells were seeded in 96-well plates for 24 h. After
they proliferated to about 90% confluence, the cells were added
into 50~100 µL MTT solution (M-2128, Sigma) and cultured at
37°C for 2 h. The results were measured in a microplate
spectrophotometer (Molecular Devices) at 540 nm.

Cell Apoptosis Assay
Breast cancer cells were rinsed by cold PBS twice, collected
and stained using the Annexin-V/PI kit (Biosource, Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s protocol.
Stained cells were analyzed by flow cytometry (Becton Dickinson
canto II, BD, NJ, USA). Data were analyzed using Flowjo software
(Three Star, Inc., Ashland, OR, USA).

Colonies Formation Assay
For measuring cellular clonogenicity, 1 × 10⁵ cells were seeded
into 6-well plates and treated with or without 5 Gy radiation
in the next day. Cells were then cultured for 14 days at 37°C.
The colonies were fixed and stained with Coomassie blue, and
then colony formation rate was determined by counting colonies
in each group. Finally, the colony images were observed and
recorded by a Nikon microscope (Eclipse, E1000M, Japan) (8).

Immunohistochemical Staining (IHC)
The slides of primary biopsy tissues and recurrent tumors from
patients with breast cancer were tested by immunohistochemistry
(IHC) using Vectastain ABC kit and DAB Peroxidase Substrate
kit SK-4100 (Vector Laboratories, Burlingame, CA, USA). The
prepared tumor slides were firstly deparaffinized, hydrated, and
then covered with blocking buffer for 1 h after heat-induced
epitope retrieval. The slides were incubated with anti-CPT1A
(Cell Signaling Technology, #12252) and anti-CPT2 (Santa Cruz,
sc-20671) at 1:200 at 4°C overnight, followed by washing with
PBST three times, and then incubated with the secondary
antibody for 30 min at RT. The slides were then covered with
ABC solution for 30 min on the shaker at RT. The slides were
incubated with DAB solution about 2 min and then transferred
to hematoxylin, HCl solution and Li2CO3 solution quickly
several times. Finally, the slides were dehydrated and sealed.
The slides were observed and recorded by Nikon microscope
(Eclipse, E1000M).

CRISPR-Mediated Gene Editing
The single guide RNA (sgRNA) was designed according the
CRISPR Design in Zhang Lab https://zlab.bio/guide-design-
resources. We created oligonucleotide to target genes CPT1A
and CPT2. The sgRNA sequences are designed as follows:
human CPT1A: CTCCGGACGGGATTGACCTG; human
CPT2: CGGGGCCCCCCGGTTGGTCC. The LentiCRISPRv2
backbone was used, which contains the hSpCas9 and sgRNA
expression cassettes. Plasmids were purchased from the
Addgene plasmid repository (Addgene #52961) (https://www.
addgene.org/). Backbone LentiCRISPRv2 was annealed to
oligonucleotides following the Zhang Lab GeCKO protocol
and packaged into lentiviruses. The Lentiviral particles
were produced in HEK293T cells following the protocol from Addgene
(38), and breast cancer cells were infected with lentiviruses and
selected with 0.3 µg/ml puromycin. Western blot analysis was
performed to identify cell colonies with gene deficiency.

Proteomics of RD-BCSCs and MCF7 Cells
The protein mixture from total cell lysates of RD-BCSCs and
MCF7 was first treated with dithiothreitol and iodoacetamide
for cysteine reduction and alkylation, respectively. The protein
samples were then digested using modified sequencing-grade
trypsin (Roche, Basel, Switzerland) at an enzyme/substrate ratio
of 1:100 in 50 mM NH4HCO3 (pH 8.5) at 37°C overnight.
The peptide mixture was subsequently dried in a Speed-vacuum and desalted by employing OMIX C18 pipet tips (Agilent Technologies, Santa Clara, CA, USA), reconstituted in water and subjected to LC-MS and MS/MS analyses on a Q Exactive Plus mass spectrometer equipped with a nanoelectrospray ionization source. Samples were automatically loaded from a 48-well microplate autosampler using an EASY-nLC 1200 system (Thermo Fisher Scientific, Rockford, IL, USA) at 3 μL/min onto a biphasic precolumn (150 μm i.d.) comprised of a 3.5-cm column packed with 5 μm C18 120 Å reversed-phase material (ReproSil-Pur 120 C18-AQ, Dr. Maisch). The biphasic trapping column was connected to a 20-cm fused-silica analytical column (PicoTip Emitter, New Objective, 75 μm i.d.) with 3 μm C18 beads (ReproSil-Pur 120 C18-AQ, Dr. Maisch). The peptides were then separated using a 180-min linear gradient of 2–45% acetonitrile in 0.1% formic acid and at a flow rate on 250 nL/min. The mass spectrometer was operated in a data-dependent scan mode. Full-scan mass spectra were acquired in the range of m/z 350–1,500 using the Orbitrap analyzer with a resolution of 70,000. Up to 25 of most abundant ions found in MS with a charge state of 2 or above were sequentially isolated and collisionally activated in the HCD cell with collision energy of 27 to yield MS/MS.

Bioinformatics Analysis
Maxquant (Version 1.5.2.8) was used to analyze the LC-MS and MS/MS data for the identification and quantification of proteins in the LFQ mode (39). The maximum number of mis-cleavages for trypsin was two per peptide. Cysteine carbamidomethylation was set as a fixed modification. Methionine oxidation and phosphorylation on serine, threonine, and tyrosine were set as variable modifications. The tolerances in mass accuracy for MS and MS/MS were both 20 ppm. Maximum false discovery rates (FDRs) were set to 0.01 at both peptide and protein levels, and minimum required peptide length was six amino acids. The LC-MS and MS/MS protein data were also analyzed with functional clustering. Of all proteins in our total protein array, only proteins that showed levels of detection were submitted to DAVID Bioinformatics Resources v6.7 (https://david.ncifcrf.gov/). Parameters were established for our functions of interest with a cutoff of p < 0.05.

Category Selection of Proteomics
DAVID Bioinformatics Resources provide a wealth of information within the Gene Ontology Tool for Biological Function (40, 41). Different broad categories were generated to profile the cluster of proteins related to varied cellular functions including mitochondrial bioenergetics and lipid metabolism as well as FAO. We used the Uniprotein tagging system, UPKeyword due to the high number of hits in the protein list.

Tumorsphere Formation
Tumorsphere assay was performed as described (42). Cells were sieved with 40 μm cell strainers (Fisher, Failawn, NJ, USA) and single-cell suspensions were seeded into 60 mm Petri dishes. The cells were grown in serum-free mammary epithelial basal medium (MEBM, Lonza, Walkersville, MD, USA), supplemented with B27, 20 ng/ml EGF, 20 ng/ml basic-FGF, and 4 μg/ml heparin. Cells were then cultured for 10 days, and tumor spheres were counted under light microscopy.

Three-Dimensional (3D) Morphogenesis Assay
MCF7 and RD-BCSC cells in 40 μL plug of Matrigel (growth factor reduced and phenol red free, Becton Dickinson, Plymouth, UK) were plated to the well of an 8-well LabTek Chambered coverglass (Nunc, Rochester, USA) at 37°C for 30 min. On ice, cells were prepared at a concentration of 5,000 cells/ml in KSFM supplemented with 5 ng/ml EGF, 2% (v/v) FCS, 4% (v/v) Matrigel, and 0.2 mL of this cell solution was plated onto the Matrigel plug and incubated for 30 min at 37°C, after which 0.2 mL of growth medium was added (KSFM supplemented with 5 ng/mL EGF, 2% (v/v) FCS). Culture medium was changed every 2–3 days. At day 10, morphology was assessed by phase microscopy and cells were fixed and processed for immunofluorescence microscopy analysis.

Statistical Analysis
Statistical significance of differences was evaluated using two-tailed student t-test for two groups’ comparison or one-way ANOVA test where multiple groups were involved. p < 0.05 was considered statistically significant.

RESULTS
Mitochondrial FAO Is Enhanced in Radioresistant Breast Cancer Cells
Lipid metabolism has been linked with cancer therapy response (28–30). Here we address the question of whether reprogramming mitochondrial FAO plays a key role in breast cancer radioresistance. Two radioresistant BC (RBC) cell lines (MCF7/C6 and MDA-MB-231/C4) isolated from surviving MCF7 and MDA-MB-231 residues with HER2 induction and aggressive phenotype after chronic radiation (Figure S1A) (8, 35) showed enhanced expressions of mitochondrial FAO genes CPT1A, CPT2, HADHB, and ACAD9 (Figure 1A). We then measured the mitochondrial FAO activity by 18C-labeled unsaturated fatty acid oleate as the substrates with CPT1A specific inhibitor Etomoxir (ETX) and the FAO activator FCCP as negative and positive controls, respectively, demonstrating a significant elevation of FAO activity in MCF7/C6 vs. wild type MCF7 cells (Figure 1B). Furthermore, enhanced lipid turnover rate was detected in MCF7/C6 cells loaded with free fatty acid (FFA), which was contrasted with the markedly accumulation of FFA in the wild type MCF7 cells (Figure 1C), indicating enhanced FAO metabolism in RBC cells.

We next determined whether the FAO is enhanced in the human recurrent breast tumors compared to the primary tumors. CPT1 and CPT2 are the rate-limiting transporters and play a key role in mitochondrial long-chain FAO and lipid metabolism. Remarkably, the enhanced co-expression of CPT1A (an isoform of CPT1) and CPT2 was mostly detected in the pathological sections of recurrent BC tumors compared to the paired original biopsy specimens in a group of 12 BC...
Enhanced FAO in Radioresistant Breast Cancer

FIGURE 1 | FAO is enhanced in radioresistant BC cells and recurrent BC and linked with a poor prognosis in BC patients. (A) Western blot of a cluster of FAO enzymes and HER2 in wild type MCF7, MDA-MB-231, and their counterpart radioresistant MCF7/C6 and MDA-MB-231/C4 cells. (B) FAO activity assay of MCF7 and MCF7/C6 cells with MCF7/C6 treated with FAO inhibitor Etomoxir (40 µM) as a negative control and FAO enhancer FCCP (1 µM) as a positive control. (C) Fatty acid turnover rate in MCF7 and MCF7/C6 cells treated with or without 250 µM Free Fatty Acid (FFA; oleic acid: palmitic acid = 2:1) for 24 h before Oil Red staining.

(Continued)
patients (Figure 1D). In agreement, the TCGA database revealed a poor prognosis in BC patients with increased expression of CPT1A or CPT2 (Figure 1E) (http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp). Together, these results indicate that reprogramming mitochondrial FAO contributes to BC radioresistance and worse prognosis.

**CPT1A/CPT2 Mediated FAO Is Required for Radioresistant Breast Cancer Stem Cells**

Our previous results have indicated that mitochondrial energy enhancement is involved in BC aggressiveness due to HER2 expression (15, 43) that is confirmed in Figure 1A.

Following the standard biomarkers of breast cancer stem cells (BCSCs) (4) and our established BCSCs from MCF7/C6 with HER2 induction as radiation-derived BCSCs (RD-BCSCs; CD44+/CD24−/low/HER2+ with enhanced ALDH activity (8), we compared the tumorspheres from RD-BCSCs and MCF7 shown in Figure 2A. The tumorsphere of RD-BCSCs showed severely disorganized structure with altered distribution of cellular polarity protein (DLG, red) and enhanced HER2 expression (green), indicating an aggressive phenotype of RD-BCSCs.

Consistent with the results of RBC in Figure 1A, the key FAO enzymes, CPT1A, CPT2, and HADHB, were also enhanced in RD-BCSCs (Figure 2B), and both basal and irradiated FAO levels were elevated in RD-BCSCs whereas no significant FAO elevation was detected in irradiated MCF7 compared to basal level, although the proteomics data showed enhanced mitochondrial proteins in both irradiated MCF7 and RD-BCSCs (Figure 2C, Figures S2A, S3A, S3B), suggesting that reprogramming FAO is a unique feature of RD-BCSCs. This is further evidenced by the specifically enhanced cluster of factors in lipid metabolism rather than other cellular proteins in irradiated RD-BCSCs (47 to 81 in RD-BCSCs vs. 55 to 76 in MCF7); and the protein intensity was also more increased in irradiated RD-BCSCs (5.24-fold) contrasted to 2.31-fold in MCF7 (Figures S1B,C). The FAO inhibitor Etomoxir (ETX) significantly enhanced basal and radiation-induced apoptosis with inhibited tumorsphere formation and ERK activity in RD-BCSCs (Figures 2D–F, Figure 2B). In agreement, blocking CPT1A/CPT2 by CRISPR-mediated gene deficiency (Figure 2G), enhanced apoptosis level and reduced the tumorsphere formation in RD-BCSCs upon IR (Figures 2H–I, Figure 2C). Additional proteomics evidence suggested that mitochondrial proteins were more enriched in the RD-BCSCs compared to MCF7 cells after radiation. The total mitochondrial protein counts increased from the same basal 117 in MCF7 and RD-BCSCs to 152 and 163, 29.9, and 39.3% respectively, whereas protein intensity had a 2.64-fold increase (4.50E+10 to 1.06E+11) in RD-BCSCs compared to a 1.83-fold increase in MCF7 cells (Figures S3A,B). Additionally, we further analyzed the mitochondrial proteins and found that FAO metabolism was also demonstrated with an increased protein number, from 11 to 17, in irradiated RD-BCSCs including CPT1A and CPT2 (Figures S4A,B, Table S1), indicating that enhanced mitochondrial FAO contributes to radioresistance of RD-BCSCs.

**ERK Activation Is Linked With Mitochondrial FAO Enhancement**

To explore the key factors responsible for FAO-mediated radioresistance, we tested an array of cell proliferating factors in the two RBC cell lines by CRISPR-mediated knockout of CPT1A and CPT2 (Figure 3A). Strikingly, the activated form of ERK1/2 was absent in the CPT1A and CPT2 KO cells, although other cell growth factors including phospho-GSK3β, phospho-STAT3, and phospho-JNK were also reduced to a certain degree (Figure 3B). Alternatively, a dose-dependent inhibition of phospho-ERK and its downstream effectors was also determined in MCF7/C6 cells with increasing concentrations of ETX (Figure 3C). It turned out that 200 μM ETX could dramatically block the phosphorylation of ERK1/2. The dependence of ERK1/2 kinase in the FAO-mediated resistance was again evaluated by a rescue experiment, in which the FAO activity was inhibited by ETX and then activated by L-carnitine. As expected, the induction of phospho-ERK1/2 upon radiation was significantly inhibited by etomoxir while enhanced by L-carnitine. Of note, the combination of etomoxir and L-carnitine treatment ablated the phospho-ERK1/2 induction by L-carnitine treatment upon radiation (Figures 3D,E). Together, our inhibition and rescue experiments consistently demonstrated that FAO mediated radioresistance is linked with ERK1/2 activation for the aggressive phenotype of radioresistant breast cancer cells.

**Deficiency of CPT1A or CPT2 Reduces OCR, Cell Viability, and Slowdown Fatty Acid Turnover Rate in RBC Cells**

By comparing the metabolic features of BC cells and RBCs, we found that both the oxygen consumption rate and cell viability were enhanced in MCF7/C6 cells compared to MCF7 cells, but remarkably reduced by ETX or in CPT1A/CPT2 KO (Figures 4A,B). Additionally, ETX treatment and CPT1A/CPT2 KO increased FFA accumulation, indicating a slower fatty acid turnover (Figure 4C). The colony formation assay was used to evaluate the cell survival rates when given radiation therapy with FAO inhibition in RBCs. The colonies in the RBC MCF7/C6 and MDA-MB-231/C4 cells were more abundant than the basal clonogenic capacity of the parental MCF7 and MDA-MB-231 cells, indicating an enhanced aggressive phenotype of RBCs. However, the etomoxir treatment and
CPT1A/CPT2 KO markedly reduced the survival colony rate in MCF7/C6 and MDA-MB-231/C4 cells (Figures 5A–D). IR induced cellular apoptosis was also evaluated in the RBCs. The FAO inhibition increased radiation-induced apoptosis from 10 to 34% (etomoxir treatment), 31% (CPT1A KO), and 36% (CPT2 KO) in MCF7/C6 cells and from 3.8 to 5% (etomoxir treatment), 9.2% (CPT1A KO), and 7.7% (CPT2 KO) in MDA-MB-231/C4 cells (Figures 6A,B). FAO inhibition also reduced tumorsphere formation from 58 to 34.5 (etomoxir treatment), 26.5 (CPT1A KO), and 24.5 (CPT2 KO) with IR in MDA-MB-231/C4 cells (Figure 6C).

Together, these results indicate that CPT1A/CPT2 mediated FAO enhancement is required for the energy demands and cell survival in RBCs. In summary (Figure 7), our results reveal that
reprogramming mitochondrial FAO is the major cellular energy supplement in radioresistant breast cancer cells. Such adaptive mitochondrial energy metabolism is linked with the clinical outcome of BC patients treated with radiotherapy. We also reveal that the ERK-mediated prosurvival pathway is a potential downstream target in FAO-mediated aggressive proliferation in BC with enhanced activation of HER2 leading to promoted cell proliferation.

DISCUSSION

It is highly clinically relevant to reveal the major cellular energy driving the growth of therapy-resistant cancer cells. The concept of aerobic glycolysis in cancer metabolism (Warburg Effect), believing the deficient mitochondrial function in cancer cells, has been updated with accumulating results of active tumor metabolic to oncogenic (9) and genotoxic stress including...
ionizing radiation (16, 44, 45). A dynamic metabolic feature is linked to the adaptive reprogramming in energy supply, which is required to meet the increased cellular fuel demands for cancer cells to repair the damage and survive anti-cancer therapy. Identification of the metabolic targets required for tumor cell survival under genotoxic stress conditions such as chemoradiotherapy are necessary for improving the therapeutic efficacy. Among other hallmarks of cancer cell progression, cancer cells can adjust energy metabolism to meet the demands of cellular fuel consumption for proliferation and survival to therapeutic stress conditions (11). In this study, we revealed a unique metabolic feature in RBCs and radioresistant breast cancer stem cells (RD-BCSCs). It showed that FAO enzyme expression and mitochondrial FAO activity were enhanced in response to radiation compared to wild type breast cancer cells. Elevated mitochondrial FAO is required for cell growth and survival in response of radiation therapy. Of note, CPT1A/CPT2 expression was also elevated in human recurrent breast cancer tissues compared to biopsy tumors. CRISPR/Cas9 mediated deficiency of CPT1A/CPT2 efficiently enhanced sensitivity of RBCs and RD-BCSCs to radiation treatment. Finally, we provided evidence that mitochondrial FAO likely functions through the ERK
FIGURE 5 | Blocking CPT1A/CPT2 synergizes radiation in eliminating clonogenic RBCs cells. Representative images (A) of colonies generated with $1 \times 10^3$ MCF7, MCF7/C6, MCF7/C6 CPT1A KO, and MCF7/C6 CPT2 KO cells treated with or without 5 Gy IR, 40µM ETX, or combined. All colonies were fixed at day 14 and quantitated (B). (C,D) Same as (A,B) except that MDA231, MDA231/C4 CPT1A KO, MDA231/C4 CPT2 KO, and MDA231/C4 cells were tested. In all experiments, $n = 3$; Error bars in (B,D) represent mean ± SD; significance was determined by one-way ANOVA test, **$p < 0.01$, ***$p < 0.001$. 

Han et al. Enhanced FAO in Radioresistant Breast Cancer
FIGURE 6 | Blocking CPT1A/CPT2 enhances apoptotic cell death and inhibits tumorsphere. (A) Representative flow cytometry of MCF7/C6, MCF7/C6 CPT1A KO, MCF7/C6 CPT2 KO, and MCF7/C6 cells treated with 5-Gy IR, ETX (40 µM, 48 h), or combined (left); quantitation of apoptotic cells is shown on the right. (B) Repeated experiments with RBC MDA-MB-231/C4 and CRISPR-KO counterparts. (C) Tumorsphere assay of (B). In (A–C), n = 3; mean ± SD; significance was determined by one-way ANOVA test, *p < 0.05, ***p < 0.001.
signaling pathway to confer resistance to radiation therapy in RBCs.

Our proteomics data demonstrate a different adaptive scale of RD-BCSCs vs. wild type MCF7 cells with a higher mitochondrial protein number and density in RD-BCSCs than MCF7 cells. Such differential stress response may apply to the varied response to therapeutic radiation in primary and recurrent/metastatic breast cancers. The plasticity of human cancer cells and the genetic-independent acquisition of therapeutic resistance may be tightly associated with metabolic reprogramming. CSCs are capable of adjusting their unique metabolic plasticity in order to respond in a timely manner and adapt to hostile environments (46). The current study revealed that enhanced FAO could be a critical step for therapy-resistant cancer cells, especially cancer stem cells, to have a survival advantage, thus they could be used for identifying and developing effective metabolic targets. Altered metabolism is served as one of the hallmarks of cancer and has also been observed in CSCs (47, 48). CSCs have been identified in many types of solid tumors and often result in recurrence and both chemo- and radioresistant in tumors because of their self-renewal and tumorigenic properties (49–51). It has been shown that blocking thioredoxin- and glutathione-dependent metabolism can enhance radiation response of BCSCs (52), indicating that in addition to FAO enhancement, other metabolites could be critical for the survival advantage of CSCs. Accordingly, metabolic adjustment in the CSC populations under different therapeutic modalities should be further investigated.

Figure 7 | (A) The network of enhanced FAO in radioresistant breast cancer cells due to overexpression of mitochondrial FAO and HER2. (B) Schematic pathways of HER1/2-MEK-ERK1/2 mediated aggressive growth in radioresistant breast cancer cells due to increased mitochondrial FAO metabolism mediated by CPT1A/CPT2.
The cellular energy shift may require a different signaling network to drive cancer cell proliferation and radioresistance. Our current data also reveal a potential crosstalk between CPT1A/CPT2-mediated lipid metabolism and ERK1/2-controlled cell proliferation (Figure 7), implicating a cooperative network of mitochondrial FAO in response to radiation in resistant cancer cells. Although currently there is no direct evidence supporting mitochondrial FAO-mediated ERK1/2 activation, the enhanced mitochondrial products including ATP from TCA cycle may increase the MEK-ERK1/2 cascade. High ATP concentration is indicated in the tumor microenvironment that can activate P2Y2 receptors to enhance BC cell migration through the activation of a MEK-ERK1/2 pathway (53). In addition, mitochondrial OXPHOS can be enhanced by Cyclin B1/CDK1 that can be relocated into mitochondria by radiation leading to phosphorylation of SIRT3, a key keeper for mitochondria homeostasis at the Thr150/Ser159 (54). Furthermore, we have recently observed that mitochondrial homeostasis is enhanced by SIRT3-regulated CTP2 activity in normal mouse liver cells via FAO (unpublished data). Thus, the CPT1A/CPT2-mediated FAO activity may be differently regulated in normal and cancer cells, which warrants further studies.

In summary, this study reveals a previously unknown feature of reprogramming mitochondrial FAO in RBCs due to enhanced CPT1A/CPT2. Thus, targeting CPT1A/CPT2 as well as other mitochondrial FAO elements may serve as a metabolic target to enhance the efficacy of breast cancer radiotherapy.

DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS
JL, J JL, and SH designed the study, wrote the manuscript, and were involved in revising the manuscript. SH, RW, and MF performed experiments with the help of NJ, BX. LZ, XZ, AB, MC, JH, and AV helped to analyze the data, prepare and revise the manuscript. H-WC provided the instruction for CRISPR technology. WM and YW generated and analyzed the proteomics data. All authors have approved the final version.

FUNDING
This work was partially supported by National Cancer Institute Grants RO1 CA152313 (to JL) and University of California Davis NCI-designated Comprehensive Cancer Center supported by the CCSG Grant awarded by the National Cancer Institute (Dr. Primo Lara; NCI P30CA093373). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.

ACKNOWLEDGMENTS
We thank Dr. Irmgard Feldman at the UC Davis Comprehensive Cancer Center Biorepository which was funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373) in sharing human breast cancer specimens.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/onco.2019.01201/full#supplementary-material

Figure S1 | (A) Schematic representation of the process for generating RBCs and RD-BCSCs. (B) Functional clustering of proteomics of MCF7 and RD-BCSCs via DAVID bioinformatics indicating the protein numbers in categories inducing lipid metabolism, oxidation reduction, DNA repair, stress response, glycolysis, and ATP synthesis in MCF7 cells with or without IR. The intensities of proteins in lipid metabolism were shown in right. (C) Repeated proteomics analysis with RD-BCSCs cells, note a group of key FAO enzymes including CPT1A and CPT2 were enhanced by radiation (marked in red in the right).

Figure S2 | (A) FAO measured in MCF7 and RD-BCSCs cells with or without 5 Gy IR treatment for 24 h. RD-BCSCs treated with 40 µM Etomoxir (ETX) were used as FAO inhibition control, and RD-BCSCs cells treated with 1 µM FCCP as an FAO enhancement control. (B) Radiation-induced apoptotic cell death measured by Annexin-V/PI flow cytometry in RD-BCSCs cells, RD-BCSCs treated with 5 Gy IR, ETX (200 µM, 48 h) or combined. (C) Repeated experiment in (B) using RD-BCSCs CPT1A KO and RD-BCSCs CPT2 KO cells.

Figure S3 | (A) Mitochondrial fractions were prepared from MCF7 and RD-BCSCs cells treated with or without 5 Gy IR treatment and analyzed by LC-MS and MS/MS on a Q Exactive Plus mass spectrometer. Numbers of proteins detected comparing MCF7 and RD-BCSCs before and after IR are shown on the left. Percentage of enhanced quantitation of the increased protein numbers by radiation are shown in the pie on the right. (B) The intensities of mitochondrial protein expression of MCF7 and RD-BCSCs treated with +/+ IR are shown.

Figure S4 | (A) Functional clustering of mitochondrial proteins via DAVID bioinformatics show the relatively high enhancement of protein numbers in lipid metabolism, oxidation reduction and ATP synthesis in the mitochondria of irradiated RD-BCSCs. (B) The two key enzymes in mitochondrial FAO metabolism, CPT1A, and CPT2 (in red), were enhanced by IR in RD-BCSCs.

Table S1 | The cluster of proteins involved in fatty acid metabolism enhanced by radiation in RD-BCSCs. The mitochondrial proteomics data were generated with mitochondrial proteins isolated from RD-BCSCs treated with or without IR, followed by digestion with trypsin and analyses by LC-MS and MS/MS on a Q Exactive Plus mass spectrometer. The 17 listed proteins were detected in the proteomic analysis of mitochondrial proteins of RD-BCSCs and classified by UniProtein under the category Lipid Metabolism. The gene symbols, descriptions, and comparison with or without 5 Gy IR are shown in the table, and the CPT1A/CPT2 are marked with yellow.

REFERENCES
1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. (2011) 378:1707–16. doi: 10.1016/S0140-6736(11)61629-2
2. Orecchia R. Breast cancer: post-mastectomy radiotherapy reduces recurrence and mortality. Nat Rev Clin Oncol. (2014) 11:382. doi: 10.1038/nrclinonc.2014.95
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. (2001) 414:145–61. doi: 10.1038/35102167
4. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol. (2010) 28:4006–12. doi: 10.1200/JCO.2009.27.5388
5. Jameel J, Rao V, Cawkwell L, Drew P. Radioresistance in carcinoma of the breast. Breast. (2004) 13:452–60. doi: 10.1007/breast.2004.08.004
6. Rich NJ. Cancer stem cells in radiation resistance. Cancer Res. (2007) 67:9890–4. doi: 10.1158/0008-5472.CAN-07-0895
7. Diehn M, Cho RW, Lobo NA, Kalisky T, Drieu MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. (2009) 458:780–3. doi: 10.1038/nature07733
8. Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res. (2012) 18:6634–47. doi: 10.1158/1078-0432.CCR-12-1436
9. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. (2012) 21:297–308. doi: 10.1016/j.ccr.2012.02.014
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
11. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cell. (2012) 148:275–88. doi: 10.1016/j.cell.2012.02.012
12. Xie B, Wang S, Jiang N, Li JJ. Cyclin B1/CDK1-regulated mitochondrial metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. (2014) 74:7498–509. doi: 10.1158/0008-5472.CAN-14-0844
13. Lu CL, Qin L, Liu HC, Candas D, Fan M, Li JJ. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition—a Warburg-reversing effect. PloS ONE. (2015) 10:e0121046. doi: 10.1371/journal.pone.0121046
14. Wang Z, Fan M, Candas D, Zhang TQ, Qiu L, Eldridge A, et al. Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression. Dev Cell. (2014) 29:217–32. doi: 10.1016/j.devcel.2014.03.012
15. Harbauer AB, O’Reilly M, Gerber C, Herman JS, Rao S, Schonfisch B, et al. Cell cycle-dependent regulation of mitochondrial preprotein translocase. Science. (2014) 346:1109–13. doi: 10.1126/science.1261253
16. Salazar-Roa M, Malumbres M. Fueling the cell division cycle. Trends Cell Biol. (2017) 27:69–81. doi: 10.1016/j.tcb.2016.08.009
17. Yasui H, Yamamoto K, Suzuki M, Sakai Y, To T, Nagane M, et al. Lipophilic triphenylphosphonium derivatives enhance radiation-induced cell killing via inhibition of mitochondrial energy metabolism in tumor cells. Cancer Lett. (2017) 390:160–7. doi: 10.1016/j.canlet.2017.01.006
18. Robertson-Tessi M, Gillies RI, Gatenby RA, Anderson AP. Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. (2015) 75:1567–79. doi: 10.1158/0008-5472.CAN-14-1428
19. De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith DL, Sanchez-Alvarez R, et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget. (2015) 6:14777–95. doi: 10.18632/oncotarget.4403
20. Favre C, Zhdanov A, Leahy M, Papkovsky D, O’Connor R. Mitochondrial pyrimidine nucleotide carrier (PNC1) regulates mitochondrial biogenesis and the invasive phenotype of cancer cells. Oncogene. (2010) 29:9964–76. doi: 10.1038/onc.2010.146
21. Robertson-Tessi M, Gillies RI, Gatenby RA, Anderson AP. Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. (2015) 75:1567–79. doi: 10.1158/0008-5472.CAN-14-1428
22. Hande M, Kaur A, Chander K, Kaur H, Singh D, Kaur N, et al. Mitochondrial pyrimidine nucleotide carrier (PNC1) regulates mitochondrial biogenesis and the invasive phenotype of cancer cells. Oncogene. (2010) 29:9964–76. doi: 10.1038/onc.2010.146
44. Hagenbuchner J, Oberacher H, Arnhard K, Kiechl-Kohlendorfer U, Ausserlechner MJ. Modulation of respiration and mitochondrial dynamics by SMAC-mimetics for combination therapy in chemoresistant cancer. Theranostics. (2019) 9:4909–22. doi: 10.7150/thno.33758

45. Pitroda SP, Wakim BT, Sood RE, Beveridge MG, Beckett MA, MacDermed DM, et al. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. (2009) 7:68. doi: 10.1186/1741-7015-7-68

46. Perusina Lanfranca M, Thompson JK, Bednar F, Halbrook C, Lyssiotis C, Levi B, et al. Metabolism and epigenetics of pancreatic cancer stem cells. Semin Cancer Biol. (2018) 57:19–26. doi: 10.1016/j.semcancer.2018.09.008

47. Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res. (2016) 18:55. doi: 10.1186/s13058-016-0712-6

48. Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. Br J Cancer. (2016) 114:1305. doi: 10.1038/bjc.2016.152

49. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. (2008) 8:545–54. doi: 10.1038/nrc2419

50. Karakala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. (2008) 26:2813–20. doi: 10.1200/JCO.2008.16.3931

51. Bertrand G, Maalouf M, Boivin A, Battiston-Montagne P, Beuve M, Levy A, et al. Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev. (2014) 10:114–26. doi: 10.1007/s12015-013-9467-y

52. Rodman SN, Spence JM, Ronnfeldt TJ, Zhu Y, Solst SR, O’Neill RA, et al. Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and glutathione-dependent metabolism. Radiat Res. (2016) 186:385–95. doi: 10.1667/RR14463.1

53. Chadet S, Jelassi B, Wannous R, Angoulvant D, Chevalier S, Besson P, et al. The activation of P2Y2 receptors increases MCF-7 breast cancer cells migration through the MEK-ERK1/2 signalling pathway. Carcinogenesis. (2014) 35:1238–47. doi: 10.1093/carcin/bgt493

54. Liu R, Fan M, Candas D, Qin L, Zhang X, Eldridge A, et al. CDK1-mediated SIRT3 activation enhances mitochondrial function and tumor radioresistance. Mol Cancer Therap. (2015) 14:2090–102. doi: 10.1158/1535-7163.MCT-15-0017

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.